1 Introduction to the Mesothelioma Applied Research Foundation
2 Who We Are Mission Statement The Meso Foundation is the only national non-profit dedicated to eradicating mesothelioma as a life-ending disease. We : Fund peer reviewed research Advocate to secure federal funds for mesothelioma research and raise awareness of mesothelioma Provide education and support for patients.
3 Leadership Board of Directors, Chair Hanne Mintz Science Advisory Board, Chair Dr. Lee Krug Executive Director Mary Hesdorffer, NP Chief Operating Officer Melinda Kotzian
4 Board of Directors * personally impacted by Mesothelioma Hanne Mintz*, Chair Los Angeles, CA Michael Becich, MD, PhD University of Pittsburgh Don Bendix* Northridge, CA General Steven Blum Reisterstown, MD David S. Ettinger, MD Johns Hopkins Medical Institution Jocelyn Farrar*, DNP Mount Airy, MD Erica Iacono* New York, NY Lee Krug, MD Memorial Sloan-Kettering Cancer Center Ted Lackner* Delmar, NY Michael S. Lagana* Belleplain, NJ
5 Board of Directors, cont d Terry Lynch International Association of Heat and Frost Insulators and Allied Workers Richard Mosca* West Nyack, NY Leon Pendarvis* Croton-on-Hudson, NY In Memoriam Congressman Bruce F. Vento*
6 Science Advisory Board Lee Krug, MD, Chair Memorial Sloan-Kettering Cancer Center H. Richard Alexander, MD University of Maryland Medical Center Alain Borczuk, MD Columbia University Michele Carbone, MD, PhD University of Hawaii Marc de Perrot, MD University Health Network Linda Garland, MD University of Arizona Cancer Center Stephen Hahn, MD University of Pennsylvania Raffit Hassan, MD National Cancer Institute Margaret Huflejt, PhD New York University, School of Medicine Hedy Lee Kindler, MD University of Chicago Brooke Mossman, PhD University of Vermont College of Medicine Anna Nowak, PhD University of Western Australia
7 Science Advisory Board, cont d Kenneth E. Rosenzweig, MD Memorial Sloan-Kettering Cancer Center Jeremy Steele, MD St. Bartholomew's Hospital David Sugarbaker, MD Brigham & Womens Hospital Robert N. Taub, MD, PhD Columbia University Anne S. Tsao, MD MD Anderson Cancer Center Haining Yang, MD, PhD Cancer Research Center of Hawaii, University of Hawaii Marjorie Zauderer, MD Memorial Sloan-Kettering Cancer Center
8 The Meso Community Patients Family and Friends Caregivers Doctors and RN s Scientists/Researchers/Pharmaceutical Companies Advocates (for Congress and for Public Awareness) Law Firms representing patients
9 What We Do Awarded over $8.2 Million for Research since 2000 Advocate to raise awareness and influenced $8.8 million in federal research funding to date Advocacy Research Meso Foundation Education/ Support Educate tens of thousands about mesothelioma Provide medical guidance to thousands of meso patients, families, and caregivers
10 Social Media
11 Public Facebook Page Mesothelioma Applied Research Foundation (1,368 Likes) facebook.com/curemesothelioma Group Cure Mesothelioma (2,087 members)
12 Online Support Groups Mesothelioma Survivors and Caregivers Group (275) Mesothelioma Q& A Group (148) Mesothelioma Warriors Caregivers Group (48) Caregiver Conversations (132) Mesothelioma Loss Group (72)
13 Research Over the last twelve years, the Meso Foundation has awarded 86 peerreviewed research grants totaling $8.2 million through our grant program National Institute of Health SPORE Specialized Programs of Research Excellence Meso Foundation Collaborating with: University of Hawaii University of Pennsylvania New York University Mayo Clinic University of Minnesota
14 Research Grant Program $8.2 million to 86 projects from 7 countries At the end of our peer-review process, an approved application will have moved through three review cycles, be assessed by no less than 6 SAB members, be scrutinized by at least one expert in their particular field and approved by the two governing bodies of the funding organization.
15 Research Grant Program 148 resulting publications in scientific journals such as: Cancer Research Clinical Cancer Research Lung Cancer International Journal of Oncology European Journal of Cancer Journal of Thoracic Oncology International Journal of Cancer Journal of Molecular Medicine
16 Example of research funded Cecilia Camacho-Hubner, MD St. Bartholomews Hospital, William Harvey Research Institute, University of London, England Title: Development of Novel Therapeutic Strategies for Malignant Pleural Mesothelioma: Targeting the IGF System
17 Specialized Programs of Research Excellence (SPORE) The Foundation is actively engaged in the process of submitting for a SPORE grant The program will fund 5-year grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of mesothelioma
18 SPORE SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resource core facilities (cores), improved research model systems, and collaborative research projects with other institutions.
19 SPORE The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the 5 year term of the grant.
20 SPORE Must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in mesothelioma translational science.
21 Collaborators SPORE University of Hawaii New York University University of Pennsylvania University of Pittsburgh University of Minnesota Mayo Clinic National Cancer Institute
22 Achieving our Mutual Goals A TISSUE BANK: Develop the best annotated tissue, serum, plasma, etc. bank using surgical and clinical based specimens PROTOCOLS TO GROW THE BANK: Get specimens from every patient available
23 Achieving our Mutual Goals NEW PLATFORMS: Collaborate with experts in the field in novel technologies and absorb these technologies in the lab to build a varied portfolio for the technologies under investigation FIND COHORTS YOU DON T HAVE: Reach out and collaborate with groups that have cohorts that are pre-disease in order to study early detection as well as carcinogenesis
24 Achieving our Mutual Goals FOCUS THE RESEARCH: Concentrate on biomarkers of different kind which could be validated Prognostic Early Detection Monitoring
25 Achieving our Mutual Goals BUILD CONSORTIUMS FOR FUTURE VALIDATION AND DATA SHARING: Share specimens with everybody and anybody who asks for them including other academicians and industry, and whether they are in the US or in Australia, UK, Italy, etc.
26 Survivorship Wouldn t it be nice to begin a conversation about survivorship What would it look like? The platform for surviving this disease is increased funding for research, access to clinical trials and mounting more international trials with lab correlates
27 Trials of Interest in the UK HSV1716 is a mutated herpes simplex virus cell Infects tumour cells causing them to burst Delivered directly into the pleural space Strategy of intrapleural delivery using attenuated virus is a new strategy that appears to hold much promise
28 Vinorelbine Vinorelbine has been widely used in the second line setting in mesothelioma despite the lack of a formalized trial in this setting Activity of vinorelbine has been reported in several small trials
29 Ganetespib With Pemetrexedcisplatin Ganetespib is a heat shock protein 90 inhibitor It is thought that this agent will reduce some of the resistance to Pemetrexed
30 Tremelimumab actively stimulates the immune system by enhancing the activity of the patient s T lymphocyte effector cells inhibits the activity of the T regulatory cells which physiologically switch off the response of the immune system, preventing a prolonged state of activation.
31 VS-6063 VS-6063 is an orally-available, small molecule inhibitor of focal adhesion kinase (FAK). Research on the FAK signaling pathway has revealed a critical role for cancer stem cell survival and disease progression. Merlin will be assessed prior to randomization
32 Advocacy Advocated for Department of Defense grants totaling $8.8 million to date. Advocated for the Centers for Disease Control and Prevention to fund a Meso Tissue Bank for $10 million. Senator Max Baucus, MT, and Past Chair Nicholas J. Vogelzang, MD Senators Barbara Boxer, Pat Murray, and Johnny Isakson
33 Advocacy: Current Initiatives Advocate for a federally funded Mesothelioma Research Program. Mobilize stakeholders including unions, industry and health advocates in this effort.
34 Advocacy: Meso Awareness Day National Visibility on the Today Show Proclamations in states, counties and cities Community events around the country
35 Education and Support 24/7, one-on-one consultations with our nurse practitioner, Mary Hesdorffer 6 moderated support groups for our patients, their families and caregivers Medical expert teleconferences New Patient Packets curemeso.org
36 Annual Symposium Annual Symposium - in its tenth year in 2013 Three Day Event: Community Advocacy Science All sessions available online following Symposium. Live-stream
37 Mary Hesdorffer, Nurse Practitioner Executive Director Mesothelioma Applied Research Foundation 1317 King Street Alexandria, VA (703) direct
North America s Premiere Mesothelioma Program at Princess Margaret Cancer Centre Update Report July 2014 TABLE OF CONTENTS Introduction 3 Life-Changing Programs Now Underway 5 Mesothelioma Research Program
Mesothelioma Research Program Program Update 2012 We are pleased to provide you with an update of progress made over the past year in the Mesothelioma Research Program at The Princess Margaret / University
NCRI Lung CSG Mesothelioma workshop in association with Department of Health Workshop Report The Royal Society of Medicine, London 2nd May 2014 Sponsored by: Mesothelioma workshop Workshop Report Workshop
Sex-Specific Medical Research Why Women s Health Can t Wait A Report of the Mary Horrigan Connors Center for Women s Health & Gender Biology at Brigham and Women s Hospital The Connors Center for Women
A First Look at the Volume and Cost of Comparative Effectiveness Research in the United States June 2009 www.academyhealth.org 1 Executive Summary While the health policy community debates the potential
PENNSYLVANIA STATE PLAN FOR ALZHEIMER S DISEASE AND RELATED DISORDERS FEBRUARY 2014 Pennsylvania (PA) State Plan for Alzheimer's Disease and Related Disorders (ADRD): TABLE OF CONTENTS I. EXECUTIVE SUMMARY...
Actions for End of Life Care: 2014-16 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing Trans. & Corp. Ops. Commissioning Strategy Finance
NATIONAL ASSOCIATION OF SOCIAL WORKERS NASW Standards for Social Work Practice in Health Care Settings 2005 NASW Standards for Social Work Practice in Health Care Settings National Association of Social
President s Report Supplement Program Listing and View of IOM Finances 2012 EDITION TABLE OF CONTENTS 1 Contents Letter from the President 2 Degrees of Impact 11 President s Office and Executive Office
The Miami Project is the largest and most comprehensive spinal cord research institute in the world with more than 200 scientists, researchers, clinicians, technicians, therapists and support personnel.
2009 annual report 10th Anniversary Edition organisation chart key achievements Board Mr Bill Manning Chairman Director Winthrop Professor Philip Thompson Executive Officer Ms Tineke Van der Eecken Celebration
Malignant Mesothelioma Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies Harvey I. Pass, MD Chief, Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Harper
REPORT State-based Home Visiting Strengthening Programs through State Leadership Kay Johnson February 2009 The National Center for Children in Poverty (NCCP) is the nation s leading public policy center
Standards for the Design, Conduct, and Evaluation of Adaptive Randomized Clinical Trials Michelle A. Detry, PhD, 1 Roger J. Lewis, MD, PhD, 1-4 Kristine R. Broglio, MS, 1 Jason T. Connor, PhD, 1,5 Scott
University of Massachusetts Medical School MA Expert Panel on End of Life Report Looking Forward: 2014 and Beyond Presented by: UMass Medical School 333 South Street Shrewsbury, MA 01545 http://commed.umassmed.edu
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
CareerS in Psychology [ Psychologists Conduct Research Apply Science Provide Health Care Teach and Study Learning Promote Community and Individual Well-Being Advise Business, Industry, and Policymakers
Should I Enter a Clinical Trial? A Patient Reference Guide for Adults with a Serious or Life-Threatening Illness A Report by ECRI Commissioned by AAHP ECRI February 2002 Should I Enter a Clinical Trial?
Biomedical Research Workforce Working Group Report BIOMEDICAL RESEARCH WORKFORCE WORKING GROUP REPORT A Working Group of the Advisory Committee to the Director National Institutes of Health June 14, 2012
REQUEST FOR PROPOSALS Grand Challenges Canada at the Sandra Rotman Centre MaRS Centre, South Tower, 101 College Street, Suite 406, Toronto, Ontario, Canada M5G 1L7 T 416.673.6568 F 416.978.6826 E email@example.com
Quality End-of-Life Care Coalition of Canada La Coalition pour des soins de fin de vie de qualité de Canada Introduction Over the past 10 years, the 30 national organizations that are members of the Quality
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: ) Chapter 11 ) W.R. GRACE & CO., et. al., ) Case No. 01-01139 (JJF) ) Jointly Administered Debtors. ) OFFICIAL COMMITTEE OF ASBESTOS
Developing an Effective Health Care Workforce Planning Model Contents Executive Summary...1 Getting Started with a Workforce Planning Model...2 Data Collecting, Understanding, and Using...3 Strategy Understanding
FDA Report FDA ACTION PLAN TO ENHANCE THE COLLECTION AND AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA August 2014 Table of Contents Introduction and Background... 1 FDA Action Plan to Enhance the Collection
1 ontrac@petermac Victorian Adolescent & Young Adult Cancer Service A practice framework for working with 15 25 year-old cancer patients treated within the adult health sector Dr Susan Palmer & Associate